U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31NO3.ClH
Molecular Weight 393.9481
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYBUTYNIN CHLORIDE, (R)-

SMILES

CCN(CC)CC#CCOC(=O)[C@](c1ccccc1)(C2CCCCC2)O.Cl

InChI

InChIKey=SWIJYDAEGSIQPZ-FTBISJDPSA-N
InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H/t22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H31NO3
Molecular Weight 357.4873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
A population pharmacokinetic model with time-dependent covariates measured with errors.
2004 Jun
Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations.
2004 Nov 15
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices.
2005 Mar 21
Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.
2007 Jul 13
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.
2008 Feb 2
Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor.
2008 May 15
Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease.
2009 Sep
Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms.
2010
Medical management of overactive bladder.
2010 Apr
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
2010 Sep 14
Patents
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:59:11 UTC 2021
Edited
by admin
on Sat Jun 26 02:59:11 UTC 2021
Record UNII
JWB87T68BN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYBUTYNIN CHLORIDE, (R)-
Common Name English
BENZENEACETIC ACID, .ALPHA.-CYCLOHEXYL-.ALPHA.-HYDROXY-, 4-(DIETHYLAMINO)-2-BUTYN-1-YL ESTER, HYDROCHLORIDE (1:1), (.ALPHA.R)-
Systematic Name English
4-(DIETHYLAMINO)-2-BUTYN-1-YL (.ALPHA.R)-.ALPHA.-CYCLOHEXYL-.ALPHA.-HYDROXYBENZENEACETATE HYDROCHLORIDE (1:1)
Systematic Name English
OXYBUTYNIN HYDROCHLORIDE, (R)-
Common Name English
Code System Code Type Description
PUBCHEM
11349918
Created by admin on Sat Jun 26 02:59:11 UTC 2021 , Edited by admin on Sat Jun 26 02:59:11 UTC 2021
PRIMARY
FDA UNII
JWB87T68BN
Created by admin on Sat Jun 26 02:59:11 UTC 2021 , Edited by admin on Sat Jun 26 02:59:11 UTC 2021
PRIMARY
CAS
1207344-05-5
Created by admin on Sat Jun 26 02:59:11 UTC 2021 , Edited by admin on Sat Jun 26 02:59:11 UTC 2021
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER